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Abstract
The  implication  of  oxidative  stress  as  primary  mechanism  inducing  doxorubicin  (DOX)  cardiotoxicity  is  still
questionable  as  many  in  vitro  studies  implied  supra-clinical  drug  doses  or  unreliable  methodologies  for  reactive
oxygen  species  (ROS)  detection.  The  aim  of  this  study  was  to  clarify  whether  oxidative  stress  is  involved  in
compliance with the conditions of clinical use of DOX, and using reliable tools for ROS detection. We examined the
cytotoxic mechanisms of 2 µM DOX 1 day after the beginning of the treatment in differentiated H9c2 rat embryonic
cardiac cells. Cells were exposed for 2 or 24 h with DOX to mimic a single chronic dosage or to favor accumulation,
respectively. We found that apoptosis was prevalent in cells exposed for a short period with DOX: cells showed typical
hallmarks  as  loss  of  anchorage  ability,  mitochondrial  hyperpolarization  followed  by  the  collapse  of  mitochondrial
activity, and nuclear condensation. Increasing the exposure period favored a shift to necrosis as the cells preferentially
exhibited  early  DNA  impairment  and  nuclear  swelling.  In  either  case,  measuring  the  fluorescence  lifetime  of
1-pyrenebutyric  acid  or  the  intensities  of  dihydroethidium  or  amplex  red  showed  a  consistent  pattern  in  ROS
production which was a slight increased level far from representative of an oxidative stress. Moreover, pre-treatment
with dexrazoxane provided a cytoprotective effect although it failed to detoxify ROS. Our data support that oxidative
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Introduction
The anthracycline compound doxorubicin (DOX), also called adriamycin, is an anti-cancerous reagent widely used for
clinical treatment of many tumors. The mechanisms linked to its anti-tumoral effect were extensively characterized (see
[ 1 ] for review). Briefly, DOX was reported to impair DNA by interfering with the topoisomerase II (TOP2) enzyme [ 2 ]
or by forming DOX-DNA adducts [ 3 ]; to disrupt mitochondrial activity [ 4 ]; or to induce an overproduction of reactive
oxygen species (ROS), i.e., oxidative stress, that damages the cells [ 5 , 6 ]. While its chemotherapeutic efficiency is
acknowledged, DOX also induces cardiotoxicity at cumulative doses exceeding 450–600 mg/m  [1 , 6 , 7 ]. Although a
matter of debate [ 1 ], DOX cardiotoxicity is thought to be due to induction of apoptosis [ 5 , 8 – 10 ] resulting from
oxidative stress [ 5 , 6 , 9 , 11 , 12 ]. The clinical use of compounds that detoxify ROS has been advocated as adjunctive
therapy [ 6 ]. Accordingly, the bisdioxopiperazine agent dexrazoxane (DXR) showed a successful cardioprotection in the
clinical setting [ 5 , 6 , 13 ] that was proposed to result from its metabolic bioactivation into rings-opened metal
ion-chelating forms that display an antioxidant activity [ 14 , 15 ].
Nevertheless, the implication of an oxidative stress as a primary mechanism of DOX cardiotoxicity remains questionable.
A major issue comes from the inherent limitations of the in vitro cultured cell models for mimicking in vivo conditions.
As primary cardiomyocytes require being isolated from sacrificed animals and are difficult to handle in long-term
culture, toxicological assays are alternatively carried out in in vitro cardiac cell models. To date, the H9c2 immortalized
cell line is the most used cell model for in vitro studies of DOX cardiotoxicity [ 8 – 10 , 12 , 16 – 19 ]. These cells are
proliferating myoblasts derived from the embryonic rat ventricular myocardium, which have the ability to be
differentiated into cardiac muscles [ 20 ]. However, concerns have been raised about the suitability of the H9c2 cells as
model of myocardium since they are commonly used under proliferation state in most of reported cardiotoxicity studies
[ 8 – 10 , 12 , 16– 19 ], while differentiated cardiomyocytes without proliferative activity mainly comprise the adult heart
in vivo. Consequently, the relevance of the conclusions made by the in vitro studies on DOX cardiotoxicity is disputed as
the cell differentiation state was found to alter dose–responses [21 ].
Furthermore, discrepancies in experimental procedures make it even more difficult to predict the events that may occur in
clinical settings. First, the intravenous administration doses of DOX per treatment cycle in patients are commonly
ranging from about 30 to 75 mg/m  (i.e., ~1.5–3 µM) [ 7 ]. Accordingly, studies involving single treatment with supra-
clinical concentrations reflect potential DOX effects [17 , 22– 24 ], yet they diverge from the conditions of clinical use,
and the conclusions of such studies should be thus considered with caution [ 1 ]. Second, DOX effects clearly depend on
the cell type, the initial dosage, and the frequency of administration. Even so, assessing DOX effects in in vitro cultures
imperatively requires taking into consideration the exposure duration as it influences the concentration eventually
accumulated within the cells. Finally, the main source of discrepancy lies in the methodologies for ROS detection. Most
of the methods that imply oxidative stress in DOX cardiotoxicity use fluorescent probes, even though their use have
several pitfalls [ 25 , 26 ]. The prominent examples are the fluorescein derivatives that were broadly used [ 8 –10 , 12 , 22 ,
27 ] in spite of their lack of specificity and sensitivity for ROS detection [ 25 , 26 ]. The limitations of the widespread
ROS sensors were recently reviewed [ 28 ]. Thus, a proper choice of the probes and a thorough understanding of their
limitations will reduce artifacts and prevent misinterpretations.
For all these reasons, examining the mechanisms implicated in DOX cardiotoxicity in vitro obliged us to follow as much
as possible the conditions of clinical use of the reagent. Here, we investigate the effect of 2 µM DOX, which corresponds
to the upper drug level clinically measured in the blood of patients [1 , 18 ]. We used two different exposure durations: a
2-h exposure followed by a 22-h drug-free period that mimics a single chronic dosage in patients, and a 24-h exposure to
promote the drug accumulation reflecting either a cumulative lower dose or a supra-clinical acute one. We selected the
H9c2 cell line as in vitro cardiac cell model. However, to stay in compliance with the differentiated state of the
cardiomyocytes in vivo, we performed experiments on differentiated H9c2 cells as previously reported [29 ]. We assessed
several functional and morphological features to highlight the cell death mechanisms linked to DOX cardiotoxicity.
Moreover, clarifying whether oxidative stress is the primary cause of DOX cardiotoxicity requires reliable methodologies
and an utmost caution in the experimental procedures. We therefore used three separate determinations for ROS
detection: two fluorescence intensity-based methods using dihydroethidium and amplex red sensors [ 28 ], and an
approach based on the measurement of the fluorescence lifetime of the 1-pyrenebutyric acid probe [ 30 – 33 ]. We




reveal that ROS levels increase only mildly reflecting the mitochondrial perturbation rather than an oxidative stress. The
cells thus commit to either apoptosis or necrosis independently of ROS levels. Additionally, while the cardioprotective
effect of DXR is usually attributed to iron chelation and ROS scavenging [ 6 , 14 , 15 ], here DXR failed to detoxify ROS
although still providing cytoprotection. Our data support the view that oxidative stress is not the primary cause of
DOX-induced cardiotoxicity in vitro.
Materials and methods
Cell culture and treatment
The H9c2 rat embryonic cardiac cell line (ATCC) was cultivated in DMEM (Flow) supplemented with 10 %
heat-inactivated fetal bovine serum (FBS; Gibco), 1 % penicillin and streptomycin (Cambrex Bio Science), and
2 mM L-glutamine (ICN Biomedicals) in 75 cm  culture flasks at 37 °C, 5 % CO . Cells were seeded every 3–4 days
when they reached 70 % confluency. As the adult heart tissue contains mostly cardiac cells that lost their proliferative
activity, i.e., differentiated cardiomyocytes, we induced the cell differentiation to be in line with the in vivo conditions.
Therefore, cells were deprived of serum by diminishing the FBS to 1 % [ 20 ] to arrest their proliferation prior to the
experiments to be performed in accordance with [29 ]. 24 h later, cells were treated with doxorubicin (DOX; Sigma-
Aldrich) up to 24 h prior analyses. DOX effects were monitored from a dose range of 20 nM to 2 µM. Moreover, effects
of constant exposure to 2 µM DOX (i.e., 24 h exposure) were compared with a shorter exposure, i.e., 2-h exposure
followed by 22 h in drug-free culture medium. Effects were also compared with cells treated with dexrazoxane (DXR;
ICRF-187; Novartis). A DXR dose of 20 µM was administrated, which corresponds to the DXR/DOX ratio 10:1 reported
to be optimal by clinical investigations [ 34 ]. Untreated differentiated cells were pre-incubated with DXR for 30 min
prior to DOX treatment according to previous studies [ 34 ]. Analyses were then performed 24 h later. Accordingly, this
time range was appropriate for the metal ion-chelating forms of DXR to be formed as maximum levels of DXR
metabolites were detected within a few hours following the administration of the parent molecule in clinical settings
[ 35 ].
Cell counting and trypan blue exclusion assay
Cells were seeded in 25 cm  culture flasks and treated as mentioned above. Floating (i.e., non-adherent) cells were
counted using a Beckman Coulter Z2 (Beckman Coulter) to assess the loss in the cell anchorage. Then, adherent cells
were harvested with trypsin/EDTA (Invitrogen) and coulter counted separately. The growth rate was calculated as
previously reported [ 30 ]. The plasma membrane integrity was monitored by trypan blue exclusion assay (Sigma-
Aldrich). Adherent and detached cells were separated and stained with trypan blue (0.5 %) in HBSS (Cambrex Bio
Science). The proportion of blue-stained cells was evaluated using a Thoma cell counting chamber.
Imaging and multiparametric analysis
Cells that committed to irreversible step of apoptosis were quantified by assessing the mitochondrial disruption as
previously reported [ 33 ]. Briefly, cells were simultaneously stained 2 h with 10 µM Hoechst 33342 (HO342) and 5 min
with 10 µM nile red (<1 % ethanol) to obtain the nuclear and cell boundaries, respectively, and 1 h with 10 µM
rhodamine 123 (Rh-123; all Sigma-Aldrich) for labeling the mitochondria. Fluorescent images were acquired using
multi-wavelength videomicrofluorometry (widefield), and a semi-automated image processing method was applied for
acquisition of both total fluorescence intensity of Rh-123 (tFI-Rh-123) and cell volume (V ). Apoptotic cells were
discriminated according to the drop of their mitochondrial potential that is traduced by the collapse of tFI-Rh-123/V
ratio values (i.e., <0.1 a.u.) [ 33 , 36 ].
Necrotic cells were identified by their nuclear swelling and loss in DNA content [ 37 , 38 ]. Following the image
processing method, the cells in the late phase of apoptosis (i.e., tFI-Rh-123/V  < 0.1 a.u.) were excluded and the data
from the remaining cell pool were subjected to a multiparametric analysis (XLSTAT-Pro software; Addinsoft) for
classifying the cells into groups reflecting the cell cycle phases: G0/G1, S, G2+M, and polyploid cells (>4 N) [33 ]. The
groups were distributed according to the cell volume, and the fluorescence intensity of HO342 (FI-HO342), which reports
the nuclear volume and the DNA content. Necrotic cells were classified into a supplemental sub-group that encompassed
cells with larger nuclei (nuclear swelling) and weaker DNA content (DNA degradation) than untreated cells in G0/G1
group. Conversely, the cells representing the earlier step of apoptosis were classified into a distinct sub-group showing
weak DNA content, nuclear condensation, and a mitochondrial hyperpolarization [ 39 – 41 ].
Spectrofluorimetry








Intracellularly, DHE is oxidized by superoxide anion to 2-hydroxyethidium and/or by other radical species to ethidium,
which in turn intercalate into nuclear DNA and exhibit similar fluorescence characteristics [ 28 ]. Although DHE is mostly
used for monitoring superoxide anion levels, here we used the fluorescent assay as an indicator for changes in overall
ROS levels. Therefore, the specific detection of 2-hydroxyethidium (i.e., extraction and HPLC analysis [ 28 , 42 ]) was
not required, and we measured the fluorescence signal output without distinguishing between the two fluorescent
products (referred hereafter as oxidized DHE). Stock solution of DHE was prepared prior to use in dimethyl sulfoxide
(DMSO; Sigma-Aldrich) into degassed atmosphere to avoid contaminating oxidation. Detached and adherent cells were
collected separately 24 h after treatment. Cells were suspended in 1 ml PBS (Gibco) at the density of 5 × 10  cells/ml,
loaded with 20 µM DHE (<0.2 % DMSO) in the dark at 37 °C for 30 min, and then washed twice prior to analysis [ 33 ].
As the maximum fluorescence emissions of ethidium and 2-hydroxyethidium are, respectively, 587 and 568 nm [ 42 ],
fluorescence spectra of oxidized DHE were recorded within the emission range of 530–700 nm after excitation of the
cells at 518 nm using a SAFAS flx spectrofluorimeter (SAFAS). To exclude the background, i.e., intrinsic fluorescence of
the cells, and the spectral crosstalk of DOX that fluoresces above 530 nm, the fluorescence spectra of non-stained cells
were acquired from both untreated- and DOX-treated populations, respectively. The contributions of each fluorescent
component were separated from the complex fluorescent spectrum recorded in stained DOX-treated cells, and the
fluorescence emitted by oxidized DHE only was quantified.
Hydrogen peroxide (H O ) levels were assessed using the amplex red (AmR) hydrogen peroxide/peroxidase assay kit
(Invitrogen). AmR is a non-fluorescent probe that does not cross the cell plasma membrane and is commonly used for
assessing extracellular H O  released from the cells. The reaction between AmR and H O  is catalyzed by horseradish
peroxidase and generates the stable fluorescent product, resofurin [ 28 ]. To ensure about detectable
concentrations of H O  from differentiated H9c2 cells under our experimental conditions, we lysed the cells for H O  to
be fully released from intracellular compartments. Stock solution and staining with AmR were performed according to
the manufacturer’s instructions. Adherent and detached cells were separately suspended in Krebs–Ringer phosphate
buffer at the density of 1.7 × 10  cells/ml and lysed for 5 min with 0.25 % Triton-X 100 (Roche Molecular
Biochemicals). Then, 100 µl AmR reaction mixture was added to 100 µl lysates and incubated for 10 min, in the dark to
avoid photo-oxidation [ 43 ]. Cell lysates were excited at 550 nm, and fluorescence emission was recorded between 560
and 600 nm using SAFAS flx spectrofluorimeter. A H O  standard curve was used to convert fluorescence intensities into
H O  equivalents (µmoles released). As positive controls, we used 10 µM DOX or 1 mM H O  solution (Sigma-Aldrich).
Time-resolved microfluorimetry
Fluorescence lifetime of the cell permeable probe 1-pyrenebutyric acid (PBA; Acros Organics) was assessed by
time-resolved microfluorimetry to quantify intracellular ROS levels as previously reported [ 30 ]. Adherent and detached
cells were suspended separately in HBSS and loaded with 0.2 µM PBA (<0.5 % ethanol) for 5 min at 37 °C. After three
washing steps, cells were suspended in 300 µl HBSS and placed in Sykes-Moore tissue-culture chambers for analysis. A
pulsed laser source excited each individual cell at 337 nm, and a 404-nm filter was applied to the emission path. The
fluorescent emission decay curves were recorded and resolved to obtain time constants (i.e., lifetimes) of PBA correlated
to ROS concentrations as previously described [30 ]. ROS levels were expressed as fold change relative to untreated cells
(control) for which a value of 1 arbitrary unit (a.u.) was assigned [ 30 ]. As negative controls, either NADPH oxidase
(NOX) was inhibited with 10 µM diphenyliodonium (DPI; Sigma-Aldrich) (<0.2 % DMSO) [ 19 ] or the mitochondrial
activity was blocked by means of fixation with Baker solution (10 % paraformaldehyde in 1 % aqueous calcium chloride)
[ 30 ]. 10 µM DOX and 1 mM H O  bolus were used as positive controls.
Statistical analysis
Statistical analyses were performed using two-tailed unpaired Student’s t test. *p ≤ 0.05, significantly different from the
control (untreated cells). A two-sample Kolmogorov–Smirnov test was used to determine whether the distribution of
ROS production values was different from the control. Data are presented as mean ± SD (standard deviations) and
averaged from at least three independent experiments.
Results
Short exposure of H9c2 cells with 2 µM DOX induces apoptosis, while constant exposure
favors necrosis
We investigated the mechanisms implicated in DOX-induced cardiotoxicity in the rat embryonic cardiac cell line H9c2.
To stay in conformity with the in vivo conditions (i.e., differentiated cardiomyocytes), we carried out all our experiments
in differentiated H9c2 cells. First, proliferating cells were seeded for 24 h in complete culture medium (10 % FBS). Then,
we induced the differentiation by depriving the cells of serum (1 % FBS) to block their growth [ 20 ]. 24 h after the
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beginning of the serum starvation, we treated the cells with 2 µM DOX. Moreover, the arrest of the cell proliferation by
serum starvation aims to exclude the interference of the cytostatic effect of DOX in the interpretation of its own cytotoxic
mechanisms resulting from the different treatment conditions. Cells were exposed with DOX for a short period (i.e., 2 h
with DOX followed by 22 h in drug-free 1 % FBS medium) or longer period (i.e., 24 h with the drug) and then monitored
for the cytotoxic effect. We first assessed the DOX effect on the cell growth by coulter counting (Fig. 1a). As expected,
reducing the FBS amount to 1 % inhibited the growth rate of untreated cells (0.4 a.u. vs. 1.8 a.u. for cells in 10 % FBS).
The slight increase we observed may result from cells that entered into the cell cycle prior to the serum starvation and
subsequently underwent the division. Negative values were obtained for growth rates in DOX-treated cells. A significant
decrease was even observed for 2-h exposure as DOX cytotoxicity led to the formation of cellular debris that could not be
detected by coulter counter.
Fig. 1
Cytotoxic effects  of  DOX on differentiated  H9c2 cells  24 h after  drug exposure for  2 or  24 h.  a  Growth  rate  of  cells
cultivated for 48 h under 10 or 1 % FBS. 24 h after the beginning of serum starvation (i.e.,  differentiation), cells were
exposed for 24 h with 2 µM DOX (DOX 24 h) or exposed for 2 h followed by 22 h incubation under 1 % FBS only (DOX
2 h) (n = 10  cells/ml per condition). *p ≤ 0.05 versus cells at t = 0 h (Student’s t test). b  Loss of cell anchorage after
treatment with 0.4 µM or c 2 µM DOX (n = 6 × 10  cells per condition). *p ≤ 0.05 versus control (Student’s t test). d Plasma
membrane  integrity  for  untreated  cells  (control),  and  2  or  24  h  exposures  with  2  µM  DOX.  Proportions  of  trypan
blue-stained cells were calculated in both adherent and detached cell groups and e for the overall populations (n = 200–300
cells  per  condition)  *p  ≤  0.05  versus  control  (Student’s  t  test).  All  counting  were  performed  in  duplicate  for  three
independent experiments. All data are mean ± SD
We further examined by microscopy whether DOX led to a loss of cell anchorage that is typically observable for cells
undergoing apoptosis [ 44 ]. One could suggest that increasing the exposure duration would enhance the drug efficiency in
inducing cell detachment. Such an assumption is confirmed when using the sub-clinical DOX dose of 0.4 µM for which
the cell detachment increased linearly with the time of exposure (Fig. 1 b). However, we found a reversed pattern when
using the clinical drug dose of 2 µM: 2-h exposure led to 80 % of detached cells, whereas 24-h exposure induced only
40 % of detached cells (Fig. 1 c). We then monitored the loss of plasma membrane integrity using trypan blue exclusion
assay. The proportions of blue-stained adherent cells were comparable between untreated and DOX-treated cells
(Fig. 1 d). Both DOX treatments enhanced similarly the proportion of blue-stained cells in the detached population
(Fig. 1 d). In the overall population, 2-h exposure led to twice as much blue-stained cells than 24-h exposure (Fig. 1e).
However, one should be cautious about the interpretation of the cell mortality yield one day after treatment as the trypan
blue method does not discriminate healthy cells from cells with membrane integrity but losing cell functions. Moreover,
primary necrosis (from dramatic damages to the cells) cannot be distinguished from secondary necrosis (latest event in
apoptosis) [ 45 ].




examined the tFI-Rh-123/V  ratio that reflects the mitochondrial function [ 33 ]. DOX treatment increased the
mitochondrial energetic state for most of the adherent cells. A mitochondrial hyperpolarization was reported to be a step
preceding mitochondrial disruption during apoptosis [ 41 ], even though an increased mitochondrial activity was also
observed during necrosis [ 46 , 47 ]. 24-h exposure with DOX led to a significant increase (1.3-fold) in mitochondrial
activity compared to untreated cells. The increase was even higher (1.8 fold) for 2 h exposure (Fig. 2 a). DOX treatments
also led to a collapse in mitochondrial function (tFI-Rh-123/V  < 0.1 a.u.) for a few amount of adherent cells (Fig. 2 a).
However, it is unlikely that such a collapse in adherent cells is mediated by DOX as a similar negligible proportion
(~5 %) was found in untreated cells (Fig. 2 b). In contrast, 2-h exposure with DOX resulted in collapsed mitochondrial
function for 70 % of detached cells versus 17 % for the longer exposure (Fig. 2 b). Our data indicate that apoptosis
hallmarks (mitochondrial disruption, loss of cell anchorage) are enhanced when cells are exposed to DOX for a short
period.
Fig. 2
Mitochondrial  disruption  induced  by  2  µM DOX treatments.  a  Mean  values  of  tFI-Rh-123/V  ratio  for  2-  and  24-h
exposures with DOX obtained in adherent cells and compared with untreated cells (control) and with a small portion of
adherent treated cells for which the mitochondrial activity collapsed (ratio <0.1) (n > 10  cells per condition). b Proportions
of adherent and detached treated cells with collapsed mitochondrial activity compared to the overall population of untreated
cells  (n  >  10  cells  per  condition).  For  all  data,  bars  are  SD and *p  ≤  0.05 versus  control  (Student’s  t  test)  for  three
independent experiments
As DOX was also widely reported to target the nucleus and impair DNA [ 48 ], we examined whether DNA was altered
using imaging and multiparametric analysis [ 33 ]. Apoptotic cells (i.e., tFI-Rh-123/V  < 0.1 a.u.) were first separated
from the cell population. Then, the cells from the remaining pool were classified according to their DNA content (i.e.,
FI-HO342), nuclear volume, and size in sub-groups reflecting the cell cycle phases [ 33 ]. Of note, although serum
starvation induces cell differentiation, the process requires many genetics and morphological changes and takes several
days to be fully completed [ 20 ]. Upon 48 h of serum starvation, the cells still share typical morphological features of
cells cultivated in 10 % FBS as shown in Fig. S1 (Online Resource 1). So that sub-groups resulting from their
classification mimic the typical cell cycle phases. The pattern of the cell cycle distribution was comparable between
untreated cells and cells exposed for 2 or 24 h to DOX: ~50 % of cells in G0/G1-like group, ~30 % in S-like phase, and
less than 20 % in G2+M-like group (Fig. 3 a). Therefore, cell detachment does not depend on the cell cycle phase. A
similar distribution was found in cells prior to the serum starvation, i.e., 0 h, as shown in Fig. S2 (Online Resource 2),
confirming that serum starvation blocked the cell proliferation.
Fig. 3
DNA alteration mediated by DOX treatments. a Cell distributions in different phases of the cell cycle. Cells with collapsed
mitochondrial function were excluded prior to the classification was performed. (n > 10  cells per condition). b Percentages
of DOX-treated cells with DNA content smaller than cells in G0/G1-like group. The proportion of adherent (in white) and
detached cells (in gray) within the populations are included. c Mean values of nuclear volumes (n > 10  cells per condition)
and  d  tFI-Rh-123/V  ratio  (n  >  10  cells  per  condition)  for  the  DOX-treated  cells  with  weak  DNA  content  (white
histograms) compared with untreated cells in G0/G1-like group (in dark). e Mean values of nuclear volumes calculated from













condition). f  Mean values and g microscopic images of the FI-HO342 for untreated and DOX-treated cells. Values were
calculated for each cell cycle group (n > 10  cells per condition). Cells were chemically detached prior to image acquisition.
For all data, bars are SD and *p ≤ 0.05 versus control (Student’s t test) for three independent experiments
Interestingly, all the cells did not satisfy the criteria for classification and formed distinct sub-groups of cells with DNA
content smaller than cells in G0/G1-like group (Fig. 3 b). 2-h exposure with DOX did not induce severe DNA damage as
only few cells (4 %) were located within the sub-group (Fig. 3 b). In contrast, 24-h exposure led to significant DNA
damage as more than 30 % of cells exhibited smaller DNA content (Fig. 3 b). These data show that increasing the
exposure duration to DOX favors DNA damage. We then monitored nuclear volume and mitochondrial activity of the
cells in these two sub-groups. Nuclear volume of the cells exposed to DOX for 2 h was smaller than of the cells in
G0/G1-like group (Fig. 3 c) indicating a nuclear condensation that is a typical apoptotic feature [ 40 ]. These cells could
not be distinguished from the other apoptotic cells beforehand as they exhibited high values of tFI-Rh-123/V  ratio
(Fig. 3 d). These findings indicate that these cells are committed to earlier apoptotic events, with the drop in
mitochondrial function happening later [ 41 ]. No change in tFI-Rh-123/V  values was observed in the cells that have
been exposed to DOX for 24 h (Fig. 3d). Remarkably, while showing a smaller DNA content, these cells exhibited
nuclear volumes higher than cells in G0/G1-like group (Fig. 3 c), indicating a nuclear swelling, which is a common
feature of cells undergoing necrosis [37 ]. We further compared the nuclear volume of cells distributed across the cell
cycle (Fig. 3 e). 2-h exposure with DOX did not alter nuclear volume, whereas it increased significantly in cells
permanently exposed to the drug. This finding confirms that longer exposure to DOX favors a nuclear swelling.
Finally, to confirm the implication of DOX in DNA alteration, we quantified the mean FI-HO342 in every phase of the
cell cycle. As DOX competes with HO342 for DNA binding sites, the decrease in mFI-HO342 is a good indicator of the
extent of DOX binding to DNA and further alteration as previously demonstrated [ 33 ]. The mFI-HO342 values correlate
with the cell distribution as values for cells in G2+M-like group are 2-fold higher than for cells in G0/G1-like group
(Fig. 3 f). Overall, 2-h exposure with DOX led to a moderate decrease in mFI-HO342 values (<20 %) whereas a strong
reduction (>50 %) was found for 24-h exposure (Fig. 3 f). Decreased mFI-HO342 and nuclear swelling for 24-h exposure
were confirmed by microscopy (Fig. 3 g). These data show that longer than 2-h exposure to DOX is required for DNA to
be quenched and deteriorated.





the exposure duration. 2-h exposure promotes loss of cell anchorage, mitochondrial hyperpolarization followed by
collapse of the mitochondrial activity, and nuclear condensation that are typical features of apoptosis [ 36 , 40 , 41 , 44 ].
24-h exposure favors DOX binding to DNA, nuclear swelling, and DNA damage that make necrosis the dominant cell
death mechanism in this case [37 , 38 ].
Both 2- and 24-h exposures to 2 µM DOX lead to only a mild increase in ROS level
Many studies support the implication of ROS in the clinical cardiotoxic effect of DOX [ 9 , 11 , 12 ]. We investigated
whether ROS production is involved in cell death events mediated by 2 µM DOX using three different methods of ROS
detection. We first assessed the changes in the magnitude of the fluorescence intensity spectrum of oxidized DHE in cells
treated for 24 h with DOX (Fig. 4 ). Here we did not aim to examine exclusively the influence of superoxide anion but
rather the DOX effect on the overall ROS levels. Therefore, we did not discriminate between the two oxidized forms (i.e.,
2-hydroxyethidium and ethidium). To make the ROS quantification reliable, we resolved the complex fluorescence
spectra to exclude the strong interference of DOX fluorescence intensity and to measure the fluorescence relying on DHE
oxidation only (Fig. 4 a–c). Without spectral correction, the DOX fluorescence contribution would lead to overestimation
of the amplitude of ROS production. Figure 4 d reveals that DOX treatment did not significantly change the ROS levels
in adherent cells showed by the mean fluorescence value of oxidized DHE. However, the high standard deviation
indicates a fluctuation in ROS level values within the treated population. In contrast, ROS levels decreased in detached
cells.
Fig. 4
ROS levels assessed by fluorescence intensity-based methods. Cells were loaded with DHE, and then 24 h after treatment
with DOX (2 µM), fluorescence spectra were recorded in a detached treated cells and compared to b untreated cells and c
adherent treated cells. Experimental fluorescence spectra (thick dark curve); fluorescence spectra of DOX (regular  dark
curve) and oxidized DHE alone (thin dark curve); differences between experimental and calculated curves (residual curve
×5). d  Mean values of both DOX and oxidized DHE intensities were calculated. (n  = 5 × 10  cells/ml per condition). e
Changes of intracellular H O  levels recorded 10 min after AmR loading in cells treated with 2 µM DOX for 24 h. Mean
values were compared between lysed detached treated cells, lysed (+TX) and non-lysed (−TX) adherent treated cells, and
lysed untreated cells (control). f Further comparison was performed with cells treated for 1 h with 10 µM DOX or 1 mM
H O . g The duration of AmR incubation with 2 µM DOX-treated cells was extended up to 1 h, and measurements were
performed every 10 min. (n = 1.7 × 10  cells/ml per condition). For all data, bars are SD and *p  ≤  0.05 versus control






Additionally, we monitored the changes in H O  level using AmR. This non-fluorescent membrane-impermeant probe
was initially designed for assessing extracellular H O  that is released by viable cells. Although H O  is not directly
measured within the intact cells, it is admitted that its extracellular level reflects its intracellular accumulation. This
fluorescent assay is certainly convenient for assessing H O  when detectable levels are commonly secreted by various
cell types (e.g., activated leukocytes) or released following plasma membrane injury that is mediated by treatments.
When this is not the case, one alternative consists in lysing the cells to artificially release the intracellular H O  in its
entirety [ 49 ]. Cells were lysed prior to AmR loading, then fluorescence intensities were measured each 10 min up to
20 min and values were converted to H O  equivalents. We assessed H O  level after lysis of untreated cells (Fig. 4 e),
and we found a weak H O  level (~0.05 µM). As control, we monitored the signal resulting from non-lysed cells (-TX)
and did not detect any significant H O  signal. 24-h treatment with 2 µM DOX led to an increase in H O  level up to
0.20 µM in adherent cells (+TX). However, such increased level remains modest when compared to cells treated with the
reagents at high cytotoxic doses. Indeed, increases of H O  levels up to 0.26 and 0.50 µM resulted from 1-h treatment
with 10 µM DOX or 1 mM H O  solution, respectively (Fig. 4 f). Of note, a discrepancy was observed between the
nominal dose of exogenous H O  solution added as a bolus (1 mM) and the level detected after cell lysis. Such a
difference can be explained by the important elimination of H O  from the medium of in vitro cultured cells [ 50 ]; the
gradient existing between external and cytosolic H O  that limits its entrance [ 51 ]; and the activation of intracellular
sites of H O  consumption (e.g., antioxidant defense systems). In any case, the increased H O  levels remained below the
intracellular steady-state concentrations (~1.0 µM) considered as necessary to induce an oxidative stress [ 52 ].
Importantly, the magnitude of the fluorescent signal output needs to be interpreted with caution as a time-dependent
amplification of the signal was observed. After 1 h of incubation of AmR, a H O  level of 0.5 µM was measured in cells
treated for 24 h with 2 µM DOX (Fig. 4 g) that may resulted from the photo-reduction of resofurin due to the irradiation
performed along the kinetics experiments [ 43 ]. This finding suggests that the DOX-mediated ROS production in
adherent cells is overestimated and is in reality more modest. In contrast, H O  did not accumulate in detached cells: the
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signal was comparable with lysed untreated cells and non-lysed treated cells, and remained unchanged even despite the
time-dependent auto-amplification of the signal (Fig. 4e, g).
Although both DHE and AmR methods revealed an analogous pattern for the ROS levels, we decided to use an additional
method to rule out the artifacts inherent to these intensity-based approaches. Accordingly, we examined the fluorescence
lifetime decay of PBA as previously reported [ 30 – 33 ]. We first monitored the sensitivity of the method for detecting
ROS in H9c2 cells using ROS inhibitors and activators (Fig. 5 a). Impeding the cellular activity by cell fixation with
Baker solution [30 ] or inhibiting NOX with DPI [ 19 ] resulted in a 2-fold decrease in ROS levels. Conversely, treatments
with supra-clinical DOX dose or H O  solution led to 1.5- and 2-fold increase, respectively. These findings are consistent
with data obtained with AmR (Fig. 4 f) and confirm the robustness of the method for ROS detection.
Fig. 5
Changes in ROS levels examined by time-resolved microfluorimetry. a ROS levels (fold control) in cells treated with DPI,
Baker solution, DOX, or H O  bolus (n = 70–140 cells per condition). *p ≤ 0.05 versus control (Student’s t test) for three
independent experiments. Data are mean ± SD. b Scatter plots of ROS levels in cells exposed for 2 h or continually with
2 µM DOX (n = 50–100 cells per condition) *p ≤ 0.05: distribution of values significantly different from untreated cells
(Kolmogorov–Smirnov test) for three independent experiments
We then assessed the effect of various DOX doses on ROS production. The drug was left in contact with the cells and
analyses were done from few hours to several days of treatment (Table 1 ). Small doses that slow down the cell growth
(20–70 nM) did not affect ROS levels. Moreover, no significant change in the mean values of ROS levels was found from
doses inhibiting cell growth (0.1–0.9 µM) to doses inducing cell death after several days (1–1.4 µM) or hours (1.7–2 µM)
except for the supra-clinical dose of 10 µM DOX. However, the standard deviations increased which reflect a large
variation in ROS levels inside the populations. We further monitored the effect of 2 µM DOX on ROS levels in both
adherent and detached cells 24 h after the beginning of the treatment (Fig. 5 b). Interestingly, while 2-h and continuous
exposures to DOX led to distinct cell death processes, a comparable slight increase in ROS levels was found (1.23 vs.
1.12 fold, respectively). While significant, such increased ROS levels appear low when compared to levels reached
already after 1 h of treatment with 10 µM DOX or 1 mM H O  solution (Fig. 5 a). Conversely, ROS levels strongly
decreased in detached cells for both DOX treatment conditions (Fig. 5 b). Therefore, the three methods used for ROS
detection show a consistent pattern of ROS production mediated by 2 µM DOX: a strong reduction of ROS production in
detached cells and a mild increase in adherent cells. Even in adherent cells, ROS production is modest compared to cells
treated with lethal doses of DOX or H O  bolus that are known to cause oxidative stress in cardiac cells [ 23 , 53 ].
Table 1
Variations of ROS production in differentiated H9c2 cells treated with various DOX doses and incubation periods
0.02–0.07 No change No change Hasinoff et al.  [ 22 ]
0.1–0.9 No change No change
↑SD
(0.1; 5 days) (0.35;
3 days)
Kluza et al. [ 8 ]
Spallarossa et al. [ 9 ]
Bernuzzi et al. [ 18 ]
Data were obtained from the fluorescence lifetime of PBA and presented as fold changes (compared to untreated cells). The arrows
indicate an increase in standard deviation (SD)
DOX left in contact with cells for 3 h









Data were obtained from the fluorescence lifetime of PBA and presented as fold changes (compared to untreated cells). The arrows
indicate an increase in standard deviation (SD)
DOX left in contact with cells for 3 h
No ROS measurements at those doses
1–1.4 No change ↑SDDetached cells: 0.65-fold
Hasinoff et al.  [ 22 ]
Choi et al. [ 17 ]
Gao et al. [ 27 ]
Bernuzzi et al. [ 18 ]
Ma et al. [ 12 ]
1.7 ↑SD ↑SD Gilleron et al. [ 19 ]
2 1.1-fold Adherent cells: 1.2-foldDetached cells: 0.56-fold
Bernuzzi et al. [ 18 ]
Tan et al. [ 10 ]
Ma et al. [ 12 ]
10 1.5-fold (1 h)
Hasinoff et al. [ 22 ]
Corna et al. [ 23 ]
Choi et al. [ 17 ]
Ludke et al. [ 24 ]
To confirm that ROS does not play a key role in DOX cardiotoxicity, we monitored the effects of DXR pre-treatment. We
assumed that DXR would act as antioxidant since it has been reported that its metal ion-chelating forms resulting from its
metabolic hydrolysis protect cardiac cells from DOX by favoring ROS scavenging [ 14 , 15 ]. Prior to DOX treatment,
cells were pre-incubated for 30 min with DXR at the DXR/DOX ratio 10:1 [ 34 ], and analysis was performed 24 h later.
We found that DXR alone did not induce any cytotoxic effect and that the growth rate was comparable with untreated
cells. In the presence of DXR, the growth rate was less reduced for 2 h exposure with DOX and even slightly increased
for 24-h exposure when compared with cells treated with DOX alone (Fig. 6 a). DXR pre-treatment did not alleviate
apoptosis mediated by 2-h exposure with DOX as the proportion of cells with collapsed mitochondrial activity (Fig. 6 b)
or with smaller DNA content and nuclear condensation (Fig. 6 c) remained unchanged. In contrast, DXR reduced the
necrotic yield. The proportion of cells with smaller DNA content and nuclear swelling due to 24 h exposure with DOX
was decreased (Fig. 6 c). Such cytoprotection is independent of DOX binding to DNA, as changes in mFI-HO342
(Fig. 6 d) were comparable with cells treated with DOX alone (Fig. 3 f). Finally, we assessed the effect of DXR on ROS
levels (Fig. 6 e). DXR alone led to a slight increase in ROS production that corroborates previous findings reporting its
weak prooxidant property [ 54 ]. Importantly, although DXR attenuated cell death, it failed to modify the ROS production
pattern resulting from DOX treatments in both detached and adherent cells (Fig. 6 e).
Fig. 6
Influences of DXR pre-treatment on DOX effects. Cells were pre-treated with 20 µM DXR and further exposed for 2 or 24 h
with 2 µM DOX. a  Growth rates (n  = 10  cells/ml per condition),  b  proportions  of  cells  with  collapsed mitochondrial
activity (n = 500–1000 cells per condition), or c weak DNA content (n = 500–1000 cells per condition), and d mean values
of the FI-HO342 for each cell cycle group (n = 500–1000 cells per condition) were calculated 24 h after the beginning of the
DOX treatment and compared with cells  treated with DOX only,  DXR only,  and untreated cells  (control).  All  data are
mean ± SD. *p ≤ 0.05 (Student’s t test) for three independent experiments. e Box plots representing the changes in ROS
levels monitored by time-resolved microfluorimetry. Cell treatments are indicated below the x-axis (n = 50–100 cells per
condition). *p ≤ 0.05: distribution of values significantly different from untreated cells (Kolmogorov–Smirnov test) for three






Taken together, our findings show that both short and continuous exposures to 2 µM DOX induce similar changes in ROS
levels, while they lead to distinct cytotoxic mechanisms. Our findings also support that ROS do not play a key role in
inducing DOX cardiotoxicity in vitro. Instead, the strict correlation of the ROS pattern with the mitochondrial activity
implies that changes in ROS levels may just occur due to the mitochondrial perturbations mediated by DOX treatment.
Discussion
Oxidative stress is commonly reported to induce DOX cardiotoxicity [ 5 , 6 , 9 , 11 , 12 ]. However, its implication as
primary cause is still questionable because of uncertainties inherent to the experimental procedures used in most of the
reports [ 8 –10 , 12 , 17 , 22 – 24 , 27 ]. Hence, in this study, we aimed to clarify in vitro the mechanisms of DOX-induced
cardiotoxicity in compliance with the clinical settings. Firstly, the clinical relevant dose of 2 µM was selected, as it
corresponds to a recommended dose (~45 mg/m ) intravenously administered per treatment cycle [ 7 , 18 ]. Secondly, we
took into consideration the potential influence of the exposure duration of the cells with the drug. Thus, DOX effects
were examined 1 day after the beginning of the treatment according to two time periods of cell exposure. We postulated
that a short period of exposure (2 h) would recapitulate the mechanisms resulting from a single chronic dosage. In
contrast, a longer period (24 h) may favor DOX accumulation and mimic effects of either cumulative lower
concentrations or acute high dose that are both likely to transiently enhance the DOX plasma levels of patients.
Importantly, while we used the H9c2 cell line as in vitro cardiac cell model, we assessed DOX effects in differentiated
H9c2 cells to remain as much as possible in conformity with the in vivo context since the adult heart tissue mostly
includes differentiated cardiomyocytes, i.e., cardiac cells without proliferative activity. Indeed, concerns have been raised
about the appropriateness of H9c2 cells for mimicking cardiac cells and investigating cardiac toxicity as they are
commonly used under their proliferation state [ 8 – 10 , 12 , 16 –19 ]. Accordingly, the reliability of the results obtained in
the proliferating cells when compared to primary cardiomyocytes was challenged since dose–responses were found being
altered by the cell differentiation state [ 21 ]. While inducing the H9c2 differentiation is a pertinent approach to elude the
above-mentioned limitation, one should mention that it may also add constraints in the experimental procedure. On the
one hand, it has been suggested that serum deprivation may induce apoptosis in the H9c2 cell culture independently of
the DOX treatment and therefore may lead to erroneous interpretation [ 16 ]. However, we did not find any change in the
baseline viability after serum depletion under our experimental conditions. On the other hand, long-term differentiation
of H9c2 myoblasts does not lead only to the formation of cardiac muscles but also to cells exhibiting skeletal muscle
phenotype [ 20 ]. Moreover, while the administration of all-trans-Retinoic acid during the differentiation forces the cells
to acquire a cardiac muscle phenotype [ 20 ], the cell population still remains heterogeneous that makes fastidious any
quantitative analyses as each phenotype requires to be discriminated. To overcome this issue, we opted for a short-term
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differentiation [ 29 ]. Cells were differentiated up to two days prior to analyses to be performed. Thus, while the
differentiation process was not fully completed [ 20 ], we believe that our approach makes suitable the use of H9c2 cells
as in vitro cardiac cell model for DOX cardiotoxicity study as it provides the following advantages: (i) arrest of the
proliferative activity in accordance with the in vivo context; (ii) removal of the risk of alteration of the dose–response
that is dependent on the differentiation state; and (iii) exclusion of the potential interference of the drug cytostatic effect
in the interpretation of the cytotoxic effects.
Morphological and functional features were examined to elucidate, which cell death pathway is implicated in DOX
cardiotoxicity. We revealed that the clinical DOX dose of 2 µM drives cells into two distinct cell death pathways
depending on the exposure duration with DOX. The mechanisms are outlined in Fig. 7 . We observed that apoptosis is the
predominant mechanism in cells exposed to DOX for a short period of time. Although DNA fragmentation is a marker of
apoptosis, it occurs in the later phase [55 ]. Therefore, the absence of considerable nuclear damage in spite of DOX
binding to DNA is not surprising. Nonetheless, we found that almost all cells lost their adherence capacity [ 44 ].
Moreover, mitochondrial activity was disrupted in two steps: a hyperpolarization occurred as early event [ 41 ] prior to the
loss of adherence ability, and preceded a collapse of the mitochondrial function [ 36 ] found in detached cells. Finally,
cells underwent a nuclear condensation [ 40 ].
Fig. 7
Schematic  representation  of  effects  of  DOX  on  cells  depending  on  the  exposure  time  of  the  drug  and  leading  to
cardiotoxicity
Despite DOX being commonly linked to induction of apoptosis [ 5 , 8 – 10 ], increasing its exposure duration favored the
cell commitment to necrosis. One could argue that fewer cells lost their membrane integrity, while it is a typical late
feature for necrotic cells [ 56 ]. However, one should also point out that the trypan blue assay cannot discriminate between
primary and secondary necrosis, or healthy cells and cells that kept their membrane integrity, but that are functionally
impaired [ 45 ]. Therefore, it is likely that the cells from the population undergoing primary necrosis did not broadly loose
their membrane integrity one day after the beginning of the treatment. Nevertheless, several other characteristic features
sustain that necrosis was predominant. Cells presented substantial DNA impairment that is a typical early event in
necrosis [ 38 ]. Such DNA damage resulted from a larger DOX binding to DNA as the drug was left in contact with the
cells for a longer period and highly accumulated. In addition, a major part of the cell population presented nuclear
swelling [ 37 ]. Furthermore, we also observed a mitochondrial perturbation that is likely to happen during necrosis
although a strong disruption is frequently assimilated with apoptosis. It is widely recognized that when the mitochondrial
activity is rapidly perturbed, the cellular energy level becomes promptly deficient and drives the cells into necrosis.
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Conversely, when the disruption is slower, the apoptogenic proteases can be activated and the cellular energetic state has
time to culminate to high level required for driving the apoptotic processes [ 46 , 47 ]. These observations are in line with
our findings that a highly increased mitochondrial activity preceded a collapse of the mitochondrial function in apoptotic
cells [ 41 ]. In contrast, the increase in mitochondrial activity was modest in necrotic cells as they did not require massive
energy source for the death events to be processed [47 ]. Finally, the majority of the cells did not lose their adherence
capacity, as only few were found detached. Necrotic and apoptotic processes can occur simultaneously and overlap within
cells [ 47 , 57 ], and their inverse relationship was known for many years [ 58 ]. Accordingly, it is likely that commitment
to apoptosis still occurred albeit less frequently and that necrosis prevailed. The shift in the balance between apoptosis
and necrosis is influenced by the onset and magnitude of mitochondrial disruption and DNA damage, which depend on
DOX accumulation within the cells. The stronger and faster the mitochondrial function and nuclear content are altered,
the most probable the cells commit to necrosis. As the time period of cell incubation with DOX influences the drug
concentration accumulated within the cells, our findings corroborate previous reports that low DOX doses induce
apoptosis whereas higher doses favor necrosis [ 18 ].
The quinone moiety of DOX gives it the ability to generate ROS through a series of reactions known as redox cycling [ 1 ,
5 ], which lead to an oxidative stress that is believed to be the cause for the cardiotoxic effect of the drug [ 5 , 6 , 9 , 11 ,
12 ]. As DOX cardiotoxicity is dose dependent [ 1 , 18 ], one could expect that prolonging the incubation time with DOX,
and thus, the drug accumulation within cells would result in enhanced ROS production. Nevertheless, our findings
challenge the current insights about the prominence of oxidative stress in DOX cardiotoxicity. Our first discrepancy is
based on the fact that short and long exposure durations with DOX-induced comparable changes in ROS levels, but
distinct cell death mechanisms. This finding supports the view that the ROS generation mediated by clinical dose of DOX
does not play a primary role in the cell decision to commit either to apoptosis or necrosis. Furthermore, our second
discrepancy with the current insights relies on the magnitude of ROS production resulting from DOX treatment. The
increase in ROS levels is too small to be assigned to an oxidative stress, but rather it is just reflecting the perturbation in
the mitochondrial electron transport chain. Our observation can be explained by the methodologies used for ROS
detection. Commonly applied methods are sources of many artifacts connected to the lack in sensitivity of the fluorescent
probes for detection of ROS [ 25 , 26 , 28 ]. The epitome of inherent limitations of such methodologies may lie in the use
of fluorescein derivatives. These probes have been widely used in studies linking oxidative stress to DOX cardiotoxicity
[ 8 – 10 , 12 , 22 , 27 ] although they are currently considered as unsuitable for ROS detection [ 28 ]. Accordingly, the
involvement of ROS in cardiotoxicity is still ambiguous, and their detection requires caution to avoid misinterpretations.
Here, we used AmR that was proposed as an alternative to fluorescein derivatives [ 28 ] and found an increase in ROS
levels too weak to be considered as a characteristic feature of an oxidative stress. Nevertheless, interpretations from this
method alone were excluded as we also monitored a time-dependent auto-amplification of the fluorescent signal reported
to be connected with the photo-reduction of the probe [ 43 ]. The results acquired with another ROS sensor, DHE [ 28 ],
however, confirmed the absence of ROS overproduction and challenge the reports that used this probe to detect an
oxidative stress [ 9 , 27 ]. Here again, a cautious use of the probe was required as an inappropriate correction of the signal,
i.e., no correction for the DOX fluorescence contribution would have led to misinterpretation. In parallel, we assessed the
fluorescence lifetime of PBA as this method does not have common artifacts inherent to the intensity-based approaches
[ 30 – 33 ]. We confirmed a similar ROS pattern, i.e., a slight ROS increase far from representative of an oxidative stress.
Additionally, our data regarding the DXR pre-treatment confirmed that DOX cardiac toxicity is not primarily triggered by
an oxidative stress. DXR is currently used for cardioprotection in patients clinically treated with anthracyclines (see for
reviews [ 1 , 6 , 13 ]). Its cardioprotective effect is usually attributed to its rings-opened metabolites resulting from
enzymatic hydrolysis, which exhibit iron chelation properties [6 ]. We used here DXR for its presumed antioxidant
activity as it is believed that DXR metabolites attenuate the iron-dependent oxidative stress mediated by anthracyclines.
Indeed, DXR has been reported to scavenge ROS in in vitro solution systems [14 , 15 ] and to improve in vivo the plasma
antioxidant activity of patients treated with epirubicin [ 14 ]. However, other findings challenge the cardioprotective role
of DXR metabolites as metal ion chelator in vitro. It has been reported that DXR reduced apoptosis induced by 1.5 µM
DOX, while its metal ion-chelating forms failed to protect cardiomyocytes although exhibiting a more efficient chelation
activity [ 59 ]. In addition, unlike other iron chelators, DXR failed to protect H9c2 cells from oxidative stress and injury
mediated by treatment with catecholamines [ 60 ]. These observations argue for the involvement of other mechanisms than
ion chelation in the cardioprotective effect of DXR. Our data support that DXR does not protect in vitro cultured cells
from DOX treatment by acting as antioxidant. Indeed, in spite of its optimal administration 30 min prior to DOX
treatment at the DXR/DOX ratio 10:1 [ 34 ], DXR failed to detoxify the mild increase in ROS levels mediated by both
short and long period of incubation of differentiated H9c2 cells with 2 µM DOX, although it still exerted a cytoprotective
effect. Further, our findings contrast with studies reporting that DXR prevents DOX-induced mitochondrial damages [ 22 ]
and attenuates apoptosis mediated by DOX in cardiomyocytes [ 59 ]. Indeed, we did not detect any attenuation of
DOX-mediated mitochondrial membrane potential disruption, and the apoptotic cell yield remained unchanged.
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Remarkably, we found that DXR rather protected the cells from necrotic cell death by relieving DOX-mediated DNA
damage, indicating that DXR is involved in a mechanism occurring within the nuclear compartment.
Although an iron-catalyzed oxidative stress is the mechanism the most frequently linked to DOX-mediated cardiotoxicity
(see for reviews [ 5 , 6 ]), many other mechanisms have also been suggested including dysregulation of intracellular
calcium homeostasis [ 5 ]; mitochondrial DNA degradation [ 61 ]; alteration of cardiac muscle gene expression [ 62 ];
perturbation of cytoskeletal and extracellular matrix proteins [ 63 ]; interference with cell survival signaling, e.g.,
neuregulin [ 64 ]. In connection with the nuclear compartment, DOX is widely recognized to act as topoisomerase 2
(TOP2) poison [ 2 ]. Interestingly, DXR has also been described to interact with TOP2 [ 65 ], and raising evidences support
that DXR cardioprotection may rather be linked to its interference with DOX on their shared nuclear molecular target
TOP2. The works carried out by Lyu et al. suggested that proteasomal degradation of TOP2β induced by DXR abolishes
DOX-mediated DNA damage in H9c2 cardiomyoblasts [ 66 ]. Next, Martin et al. compared the cardioprotective effect of
DXR with ICRF-161, a DXR derivative that is not capable of inhibiting TOP2. While both compounds exhibited
comparable efficiency in iron-chelating activity in primary cardiomyocytes, ICRF-161 failed to protect the myocardium
of a rat model of chronic anthracycline-induced cardiomyopathy unlike DXR [ 67 ]. Recently, Deng et al. confirmed in
differentiated H9c2 cells the inefficiency of ICRF-161 in reducing DNA impairment from DOX treatment. Their results
support that DXR antagonizes DOX-mediated double strand breaks by depleting TOP2β [ 68 ]. Although DXR
mechanisms have not been thoroughly investigated here, our findings support that it is more likely that DXR
cardioprotective effect on differentiated H9c2 cells is linked to its interference with DOX on TOP2-mediated DNA
cleavage rather than through a metal ion-chelating activity.
In summary, our study aimed to elucidate the implication of oxidative stress in DOX-induced cardiac toxicity in vitro.
Our investigations were conducted by following as much as possible the clinical settings. We assessed clinical relevant
doses of DOX and took into consideration the exposure duration of the drug that influences in vitro the cell uptake and
the final drug concentration accumulated within the cells. Moreover, we used H9c2 cells under differentiation state to
stay in compliance with the absence of proliferative activity of the cardiomyocytes in vivo. Accordingly, assuming that
short exposure of in vitro cultured cells with DOX is comparable with a single dose in the clinical setting, our findings
support that apoptosis is predominantly induced by this type of treatment. Moreover, if one admits that longer drug
administration promotes intracellular drug accumulation, necrosis may also occur and lead to cumulative dose-dependent
cardiomyopathy under clinical conditions. Next, our data support that oxidative stress does not act as primary mechanism
in DOX-induced cardiotoxicity and corroborate previous findings [ 69 ]. It has been reported that DOX induces a
persistent stimulation in ROS production a long time after the injection of the drug [ 70 ]. In this connection, it could be
that the slightly increased ROS production we showed may be enhanced with cumulative DOX administrations and may
eventually favor oxidative damages and further sustain the irreversible cardiomyopathy observed in clinical settings. In
addition, our data underline the importance of using reliable methodologies for in vitro studies of ROS generation to
avoid any artifacts during the data acquisition. Finally, here we support that the thorough cautions we applied on the
experimental procedure and conditions made the differentiated H9c2 cells as a fair alternative to primary cardiomyocytes
cultivated in vitro and therefore suitable for their use as in vitro cardiac cell model. However, further in vivo studies on
mammalian animals are required to unequivocally confirm the above-mentioned mechanisms described in in vitro
cultured cells.
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